The Role of Oxytocin and Cortisol as Biomarkers of Efficacy in Animal-Assisted Interventions for Patients With Major Depressive Disorder: A Narrative Review

催产素和皮质醇作为动物辅助干预治疗重度抑郁症患者疗效生物标志物的作用:叙述性综述

阅读:1

Abstract

Major depressive disorder (MDD) is a leading cause of disability worldwide, often characterized by dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and impaired social affiliation. Despite standard pharmacological treatments, a significant proportion of patients continue to struggle with treatment-resistant depression, necessitating the exploration of effective adjunctive strategies such as animal-assisted interventions (AAIs). The primary objective of this narrative review is to synthesize current neurobiological evidence regarding the efficacy of AAIs in MDD populations. Specifically, we aim to evaluate the modulation of cortisol and oxytocin as primary biomarkers and to delineate the role of C-tactile (CT) afferent pathways in mediating these physiological shifts. A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science (2000-2026), focusing on quantitative studies and meta-analyses investigating neuroendocrine responses to AAIs in depressive or high-stress populations. The evidence indicates that even brief (10-20 minute) interactions with animals can lead to a significant reduction in salivary cortisol levels, suggesting rapid HPA axis stabilization. Furthermore, oxytocin secretion, stimulated by visual and tactile contact, enhances emotional regulation. This process is further mediated by the activation of CT-tactile afferents during petting, which project to the insular cortex to promote anxiolytic effects. Comparative analysis suggests that while canine-assisted interventions yield acute stress reduction, equine-assisted therapies may influence long-term diurnal cortisol rhythms. AAIs offer a measurable, biologically grounded supportive treatment for MDD. While promising, the field requires standardized protocols and large-scale longitudinal studies to establish evidence-based guidelines for clinical psychiatric practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。